These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Is tapentadol an advance on tramadol? Guay DR Consult Pharm; 2009 Nov; 24(11):833-40. PubMed ID: 20092221 [TBL] [Abstract][Full Text] [Related]
3. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444 [TBL] [Abstract][Full Text] [Related]
5. Unique pharmacology of tapentadol for treating acute and chronic pain. Knezevic NN; Tverdohleb T; Knezevic I; Candido KD Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077 [TBL] [Abstract][Full Text] [Related]
6. Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model. Ono H; Nakamura A; Kanbara T; Minami K; Shinohara S; Sakaguchi G; Kanemasa T J Pharmacol Sci; 2014; 125(3):264-73. PubMed ID: 24965165 [TBL] [Abstract][Full Text] [Related]
11. Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs. Kögel B; Terlinden R; Schneider J Vet Anaesth Analg; 2014 May; 41(3):297-304. PubMed ID: 24576316 [TBL] [Abstract][Full Text] [Related]
12. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice. Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022 [TBL] [Abstract][Full Text] [Related]
13. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol. Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451 [TBL] [Abstract][Full Text] [Related]
14. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Butler SF; McNaughton EC; Black RA Pain Med; 2015 Jan; 16(1):119-30. PubMed ID: 25243972 [TBL] [Abstract][Full Text] [Related]
15. Tapentadol for pain: a treatment evaluation. Hartrick CT; Rodríguez Hernandez JR Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161 [TBL] [Abstract][Full Text] [Related]
16. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain. Schiene K; De Vry J; Tzschentke TM J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956 [TBL] [Abstract][Full Text] [Related]
17. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Candiotti KA; Gitlin MC Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361 [TBL] [Abstract][Full Text] [Related]
18. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice. Kögel B; De Vry J; Tzschentke TM; Christoph T Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580 [TBL] [Abstract][Full Text] [Related]
19. Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users. Stoops WW; Glaser PE; Rush CR Psychopharmacology (Berl); 2013 Jul; 228(2):255-62. PubMed ID: 23430163 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of tapentadol metabolites. Terlinden R; Kogel BY; Englberger W; Tzschentke TM Methods Find Exp Clin Pharmacol; 2010; 32(1):31-8. PubMed ID: 20383344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]